Overview

HDRUK Oxford’s expertise in health data spans:

  • Wearables and digital health technology
  • Epidemiology of major diseases, including cancer, cardiometabolic and brain health focussing on risk (factors) and prediction of pathology
  • Urgent data initiatives that involve environmental risk factors including life style and the integration of state-of-the-art molecular technology in the design and analysis of population health research
  • Preventive and clinical trials and implementation evaluation

Through robust partnerships across academia, the NHS and industry, we have established:

  • Secure scalable data infrastructures
  • Governance frameworks—that underpin reproducible research and translation

Oxford HDRUK’s ecosystem ensures that high-value, multimodal healthcare data are:

  • Curated
  • Findable, accessible, interoperable and reusable (FAIR) at scale
  • Driving population health and improvements in patient outcomes
  • Improving health service efficiency

 

Regional Co Leads

Programme Manager

  • Natasha Sahgal

 

Regional Expertise

  • Data Governance & Secure Environments

We are involved in designing and implementing a pioneering governance framework and operating model for secure data environments in partnership with the Health Research Authority and NHS England.

  • AI/ML, Predictive Analytics and Digital Health technology

Our researchers specialise in developing machine learning models for risk prediction, disease progression and decision support—spanning applications from preventive screening to precision oncology and postoperative care. Methodological advances in federated learning and explainable AI ensure both data privacy and clinical interpretability. Digital Health technology focuses on life style (physical activity, sleep), neurology (cognition, speech, gait) and cardiac function (ECG).

  • Translational methods, experimental medicine and preventive and clinical trials

We provide end-to-end support for trial design, data curation and reproducibility assessment, enabling high-quality, scalable translational research. Short- and medium-term objectives include tools for data quality assessment and reproducibility, while our long-term vision focuses on patient-centred outcomes and those at high risk based on genetic or other -omic based biomarkers.

  • Data standardisation and federated analytics

HDRUK Oxford plays a leading role in the region in harmonising real-world health data using the Observational Medical Outcomes Partnership (OMOP) Common Data Model and contributing to the European Health Data & Evidence Network (EHDEN). This work enables large-scale, federated research across international datasets without moving sensitive patient data, facilitating robust, reproducible analyses in areas such as drug safety, COVID-19, and multimorbidity. It also supports rapid regulatory-grade evidence generation for population health and policy impact.

  • Public & Patient Involvement Expertise

We co-design governance and data-use processes with patients, public contributors, and healthcare staff. Our recruitment strategy — developed with NIHR Oxford BRC Diversity in Research Group—ensures representation of under-served populations (e.g., Roma/Gypsy, homeless, LGBT, Trans). We deliver plain-language materials, cultural accommodations (e.g., prayer spaces), and regular policy reviews to support inclusive, effective engagement.

 

For more information and insight into the work of this regional network, please visit : Health Data Research UK – Oxford Region

    • Thames Valley Surrey Secure Data Environment (TVS SDE)

    Build on existing initiatives to expand the health data research infrastructure and improve secure access for approved research data that also protects the public interest.

    • Brain Health and the Dementia Trials Accelerator

    Support development of a national, secure data platform with UK DRI and HDR UK to enhance recruitment and trial readiness in dementia research. UK DRI Collaboration

    Strengthen the HDR UK network across the region and beyond, by building stronger links with existing health data research groups and establishing new collaborations to increase efficiency and translational impact.

    Deliver a programme of seminars to share knowledge and expertise with the health data research community, and enhance existing communications channels to build awareness of the region’s health data assets and services.

    • Healthcare Data Science Centre for Doctoral Training and Internships

    Continue building a strong health data science workforce by identifying and fostering new talent in internships (such as UNIQ+ and the HDR UK Black Internship Programme) and PhD students and supporting existing staff with their career aspirations

    • RECOVERY trial: This trial has identified four other life-saving treatments, and determined that 11 other treatments were ineffective, allowing healthcare systems to redirect resources. It has influenced national and international treatment guidelines and has become a model for future clinical trials, demonstrating the benefits of embedding research within healthcare systems. It has also expanded globally, supporting treatment strategies in low- and middle-income countries. It has been described as a ‘beacon of excellence and its success has been recognised by numerous awards, including an NIHR Impact Prize.

     

    • Secure Data Environment (SDE): accessing NHS data for research: We are changing the way in which this data is accessed: reducing the costs, avoiding duplication of effort, and accelerating research and development. The SDE team is extracting the data from the closed, commercial systems used for care and making it available in an open format, together with the assurance needed for high-value research and development. To do this, they break new ground in developing data governance, developed new technologies, and established a strong, supportive community of patients, the public, and healthcare professionals. More than 40 billion rows of data have been extracted from health and care organisations across the region, and more than 30 projects are already underway.

     

    • ASCEND PLUS trial: enhancing trial design through patient and public involvement: Diabetes poses a global health threat, affecting over 400 million people and significantly increasing the risk of heart attacks, strokes, and circulatory complications. In response, the ASCEND PLUS trial, led by Oxford Population Health, is evaluating oral semaglutide for type 2 diabetes through an innovative, patient-informed decentralised design. Notably, this involvement has been integral to shaping the trial’s design—informing the implementation of flexible online and telephone participation options and enhancing the clarity and accessibility of trial information, which has led to an optimized trial framework and successful regulatory and ethical approvals.

     

    • Global Population Cohorts: Population cohorts have characterised major causes of premature death from non-communicable diseases (NCDs), including hypertension, smoking, obesity (adiposity), harmful alcohol use, dyslipidaemia, diabetes, poor diet and physical inactivity. However, the precise impact of these factors can vary greatly across populations. Several large cohorts in diverse populations are now in a position to generate valuable evidence on the importance of the major risk factors for NCDs in different parts of the world, which the team aim to help mobilise and cross-link in order to advance understanding of NCDs worldwide, in collaboration with HDR Global and other partners.
    • The Indian Study of Healthy Ageing (ISHA) is a prospective blood-based cohort study of 220,000 men and women recruited from town and villages in Maharashtra. As the only study of its kind in India this will be a valuable and much needed resource. Preliminary findings, based on the first 39,000 participants, have been published and report on differences between men and women in relation to education, tobacco and alcohol use, adiposity, blood  pressure and depression.
    • The Malaysian Cohort Study is a prospective blood-based cohort study of 120,000 men and women recruited from throughout Malaysia, with DXA imaging of 5000 participants. DXA imaging from 1990 postmenopausal women showed that total adiposity was inversely associated with total bone marrow density and may be a risk factor for low bone density across diverse populations.
    • The team continues to develop and host training courses: Introduction to Epidemiology, Practical Statistics for Epidemiology using R, Nutritional Epidemiology, Introduction to Survival Analysis using R and Fundamentals of Statistical Software & Analysis.

Regional Partners